Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 May 17:3:75-85.
doi: 10.4137/JCNSD.S5729. Print 2011.

Sertindole in the management of schizophrenia

Mario F Juruena  1 , Eduardo Pondé de Sena, Irismar Reis de Oliveira
Affiliations

Sertindole in the management of schizophrenia

Mario F Juruena et al. J Cent Nerv Syst Dis. .

Abstract

Nowadays, new schizophrenia treatments are more ambitious than ever, aiming not only to improve psychotic symptoms, but also quality of life and social reinsertion. Our objective is to briefly but critically review the diagnosis of schizophrenia, the atypical antipsychotics sertindole's pharmacology, safety and status, and mainly evaluate the effects of sertindole compared with other second generation antipsychotics for people with schizophrenia and schizophrenia-like psychosis. In vitro studies showed that sertindole exerts a potent antagonism at serotonin 5-HT2A, 5-HT2C, dopamine D2, and αl adrenergic receptors. Sertindole offers an alternative treatment option for refractory patients given its good EPS profile, favorable metabolic profile, and comparable efficacy to risperidone. Due to cardiovascular safety concerns, sertindole is available as a second-line choice for patients intolerant to other antipsychotic agents. Further clinical studies, mainly comparisons with other second-generation antipsychotic agents, are needed to define the role of sertindole in the treatment of schizophrenia.

Keywords: antipsychotics; efficacy; pharmacokinetics; pharmacology; safety; sertindole.

PubMed Disclaimer

References

    1. De Oliveira IR, Juruena MF. Treatment of psychosis: 30 years of progress. J Clin Pharm Ther. 2006;31:523–34. - PubMed
    1. Wyatt RJ. Diagnosing schizophrenia. In: Lieberman JA, Murray RM, editors. Comprehensive care of schizophrenia: a textbook of clinical management. London: Martin Dunitz; 2001. pp. 1–26.
    1. Juruena MF, De Sena EP, De Oliveira IR. Safety and tolerability of antipsychotics: focus on amisulpride. Drug Healthcare and Patient Safety. 2010:205–11. - PMC - PubMed
    1. Van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 1996;124:168–75. - PubMed
    1. Wing JK, Cooper JE, Sartorius N. Measurement and classification of psychiatric symptoms: an instructional manual for the PSE and catego program. London: Cambridge University Press; 1974.

LinkOut - more resources